SCHEMBL5951009

SCHEMBL5951009

N#Cc1c(N)nc(CC(=O)O)c(C#N)c1-c1ccc2c(c1)OCCO2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 12/20 0.53
ADORA2A P29274 6/20 0.52
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 5/20 0.47
HSD17B10 Q99714 4/20 0.47
USP2 O75604 2/20 0.47
TSHR P16473 2/20 0.47
HPGD P15428 4/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
GAA P10253 3/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PDCD1 Q15116 1/20 0.43
CD274 Q9NZQ7 1/20 0.43
MAPT P10636 3/20 0.42
POLB P06746 2/20 0.42
ALOX15 P16050 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13848745 0.86 ADORA1 (0.52) ADORA1ADORA2AALDH1A1KDM4EHSD17B10
SCHEMBL13848718 0.80 ADORA1 (0.59) ADORA1ADORA2AALDH1A1KDM4EHSD17B10
SCHEMBL3342911 0.78 ADORA1 (0.59) ADORA1ADORA2AALDH1A1KDM4EHSD17B10
SCHEMBL6106928 0.75 ADORA1 (0.88) ADORA1ADORA2B
SCHEMBL3548181 0.75 ADORA1 (0.62) ADORA1ADORA2AALDH1A1KDM4EHSD17B10
SCHEMBL4024284 0.75 ADORA1 (0.58) ADORA1ADORA2AALDH1A1KDM4EHSD17B10
SCHEMBL4191367 0.75 ADORA1 (0.51) ADORA1ADORA2AALDH1A1KDM4EHSD17B10
SCHEMBL5951710 0.74 ADORA1 (0.58) ADORA1ADORA2AALDH1A1KDM4EHSD17B10
SCHEMBL3546986 0.74 ADORA1 (0.58) ADORA1ADORA2AALDH1A1KDM4EHSD17B10
SCHEMBL6104540 0.74 ADORA1 (0.65) ADORA1ADORA2AALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129255-B2 Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor BAYER AKTIENGESELLSCHAFT (DE) 2006-10-31 US disclosed
US-20040110946-A1 Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110946-A1 Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor ADORA3, ADORA1, ADORA2A ADORA1 2/4885ADORA2A 3/4885ALDH1A1 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.